Efficacy and Safety of 2 Doses of TEV-48125 Versus Placebo for the Prevention of Chronic Migraine

- Migraine
- Completed

Study Title: Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Teva Identifier: TV48125-CNS-30049 | 2015-004549-23

ClinicalTrials.gov Identifier: NCT02621931

Study Status: Completed

Trial Condition(s): Migraine

Interventions: Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years to 70 Years

Trial Duration: March 22, 2016 - April 11, 2017

Phase: Phase 3

Study Type

Interventional